| The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. | |
| | |
MedLine Citation:
|
PMID: 15030297 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chronic kidney disease (CKD) is emerging as a new health pandemic. Underlying the global rise in CKD is an increase in diabetes, hypertension and other cardiovascular risk factors leading to progressive renal dysfunction. Emerging evidence strongly suggests that achieving target blood pressure goals via inhibition of the renin-angiotensin-aldosterone system confers significant renal and cardioprotection for patients with CKD. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) lower blood pressure, reduce proteinuria and reduce both the progression of CKD and adverse cardiovascular events. The role of aldosterone inhibition and combination therapy, such as ACEI/ARB, in CKD are under investigation. As our understanding of the basic mechanisms underlying CKD progression advances, novel therapies targeting post-translational endothelial and mesangial messengers downstream from angiotensin II and aldosterone may become available for clinical use. |
| | |
Authors:
|
Keith Norris; Charles Vaughn |
Related Documents
:
|
1269097 - Relation between plasma renin activity, angiotensin, and aldosterone and blood pressure... 3440817 - Effects of hemorrhage and naloxone on adrenal release of methionine-enkephalin and cate... 15730437 - Prolongation of the qt interval in primary aldosteronism. 10760067 - Aldosterone and mineralocorticoid receptors: orphan questions. 15845157 - Comparison of segmental and global systemic ventricular function at rest and during dob... 8681337 - Nitroprusside selectively reduces ventricular preload in the stage 21 chick embryo. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 1 ISSN: 1477-9072 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2003 May |
Date Detail:
|
Created Date: 2004-04-02 Completed Date: 2004-05-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 51-63 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Charles R Drew University, Los Angeles, CA, USA. knorris@ucla.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone Antagonists
/
administration & dosage* Angiotensin-Converting Enzyme Inhibitors / administration & dosage Antihypertensive Agents / administration & dosage Drug Administration Schedule Drug Therapy, Combination Humans Kidney Failure, Chronic / drug therapy*, physiopathology Randomized Controlled Trials as Topic |
| Grant Support | |
ID/Acronym/Agency:
|
P20 MD00182-01/MD/NCMHD NIH HHS; P20-RR11145-20/RR/NCRR NIH HHS; U54RR14616/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hyperte...
Next Document: Antihypertensive drugs and arterial stiffness.